J&J(US:JNJ) ZACKS·2026-01-21 22:20分组1 - Johnson & Johnson reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.43 per share, and showing an increase from $2.04 per share a year ago, representing an earnings surprise of +1.05% [1] - The company achieved revenues of $24.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.84%, and up from $22.52 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 5.4% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $2.75 on revenues of $23.05 billion, and for the current fiscal year, it is $11.46 on revenues of $98.46 billion [7] 分组3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Eli Lilly, another company in the same industry, is expected to report quarterly earnings of $7.50 per share, reflecting a year-over-year increase of +41%, with revenues projected at $18.21 billion, up 34.6% from the previous year [9]